Pharsight

Drugs that contain Aripiprazole

1. Abilify patents expiration

ABILIFY's oppositions filed in EPO
ABILIFY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528 OTSUKA Carbostyril derivatives
Oct, 2014

(9 years ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5006528

(Pediatric)

OTSUKA Carbostyril derivatives
Apr, 2015

(9 years ago)

US9358207 OTSUKA Flashmelt oral dosage formulation
Apr, 2020

(4 years ago)

US8518421 OTSUKA Flashmelt oral dosage formulation
Jan, 2021

(3 years ago)

US8518421

(Pediatric)

OTSUKA Flashmelt oral dosage formulation
Jul, 2021

(2 years ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(2 years ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(2 years ago)

US6977257 OTSUKA Aripiprazole oral solution
Apr, 2022

(1 year, 11 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(1 year, 8 months ago)

US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution
Oct, 2022

(1 year, 5 months ago)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(1 year, 27 days ago)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(1 year, 27 days ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(3 months ago)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(a month from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(2 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(2 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(7 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(9 months from now)

US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(9 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Aug 27, 2011
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE) Dec 12, 2021
M(M-137) Jun 09, 2017
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021
New Indication(I-633) Feb 16, 2014

Market Authorisation Date: 20 September, 2006

Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute tr...

Dosage: INJECTABLE;INTRAMUSCULAR; TABLET, ORALLY DISINTEGRATING;ORAL; TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Asimtufii patents expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759351 OTSUKA Methods for administering aripiprazole
Aug, 2023

(8 months ago)

US8338428 OTSUKA Methods for administering aripiprazole
Aug, 2023

(8 months ago)

US8338427 OTSUKA Methods for administering aripiprazole
Mar, 2025

(10 months from now)

US11097007 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

US10517951 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

US11638757 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

Market Authorisation Date: 27 April, 2023

Treatment: Use of aripiprazole in extended release injectable suspension; Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

3. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
ABILIFY MAINTENA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528 OTSUKA PHARM CO LTD Carbostyril derivatives
Oct, 2014

(9 years ago)

US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5006528

(Pediatric)

OTSUKA PHARM CO LTD Carbostyril derivatives
Apr, 2015

(9 years ago)

US9089567 OTSUKA PHARM CO LTD Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(8 months ago)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(8 months ago)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(5 months from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(5 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(5 months from now)

US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(10 months from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(9 years from now)

US11648347 OTSUKA PHARM CO LTD Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Apr, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-746) Jul 27, 2020
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherap...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

4. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(2 years ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(3 months ago)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(a month from now)

US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(2 years from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(2 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(3 years from now)

US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(4 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(4 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(5 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(5 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(5 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(5 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(5 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(5 years from now)

US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(5 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(6 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(6 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(6 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(6 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(6 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(6 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(6 years from now)

US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(7 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(7 years from now)

US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(8 years from now)

US9577864 OTSUKA Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
Oct, 2033

(9 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(9 years from now)

US9787511 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US9270503 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

US10097388 OTSUKA Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Market Authorisation Date: 13 November, 2017

Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to ident...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents